INTRODUCTION 🧬
Intracellular bacterial infections pose significant therapeutic challenges due to the inability of many antibiotics to penetrate cellular membranes and reach effective intracellular concentrations. This research targets the eradication of intracellular Staphylococcus aureus, a pathogen known for its persistence within host cells and resistance to conventional treatments. To overcome this limitation, a novel drug delivery system was designed using hen egg-yolk-derived low-density lipoproteins (heLDLs) to encapsulate Ceftiofur (CEF), an antibiotic with established efficacy against S. aureus. The formulation, referred to as CEF-heLDLs, aims to facilitate targeted intracellular drug delivery, thereby enhancing antibacterial efficacy and reducing mortality associated with intracellular infections. This study presents a comprehensive evaluation of the physicochemical properties, cellular uptake mechanisms, biodistribution, and in-vitro and in-vivo antibacterial activities of CEF-heLDLs.
FORMULATION AND DRUG-LOADING CHARACTERISTICS ⚗️
The design and development of the CEF-heLDL system began with the extraction of low-density lipoproteins from hen egg yolks, a biocompatible and natural carrier. Ceftiofur was successfully loaded into these carriers, achieving a high encapsulation rate of approximately 99.31% ± 0.63% and a drug-loading efficiency of 44.48% ± 2.35%. The resulting nanoparticles demonstrated reduced particle size and increased absolute zeta potential compared to blank heLDLs, which are indicative of improved stability and dispersion. These physicochemical enhancements play a critical role in ensuring the particles remain stable in physiological environments, a prerequisite for efficient drug delivery. The high encapsulation rate and stable characteristics of CEF-heLDLs highlight the potential of heLDLs as effective nano-carriers for intracellular drug delivery.
CELLULAR UPTAKE AND LOCALIZATION 🔬
In-vitro cellular uptake studies revealed that the CEF-heLDLs enter cells via receptor-mediated endocytosis, leveraging the natural pathways of LDL receptors. Confocal microscopy confirmed the colocalization of CEF-heLDLs with lysosomes, suggesting successful intracellular trafficking of the antibiotic. This lysosomal targeting is essential for reaching intracellular compartments where S. aureus may reside. The receptor-specific entry pathway also minimizes off-target effects and enhances selective drug accumulation within infected cells. These findings validate the efficiency of the heLDL-based delivery system in overcoming cellular barriers and ensuring site-specific drug release.
BIODISTRIBUTION AND SYSTEMIC DELIVERY 🧫
In-vivo localization studies in mouse models demonstrated that CEF-heLDLs exhibit a multiorgan biodistribution profile, indicating effective systemic circulation and penetration into various tissues. This widespread distribution is advantageous for treating infections that may not be localized, providing therapeutic coverage across multiple sites. The heLDL vector ensures that the encapsulated CEF is shielded from rapid degradation or clearance, allowing for prolonged therapeutic presence and action. This property enhances the practicality of CEF-heLDLs for clinical applications in systemic and intracellular infections.
ANTIBACTERIAL EFFICACY AND MECHANISM OF ACTION 🧪
Both in-vitro and in-vivo antibacterial evaluations confirmed the superior performance of CEF-heLDLs against intracellular Staphylococcus aureus. In cellular models, CEF-heLDLs significantly disrupted bacterial cell walls and reduced intracellular bacterial counts (P < 0.001), outperforming free CEF. Animal studies further showed that CEF-heLDLs effectively reduced leukocytosis and mortality in methicillin-resistant S. aureus (MRSA)-infected mice (P < 0.001). The enhancement in antibacterial activity is attributed to the increased intracellular concentration of CEF and improved targeting, which allows the drug to act directly within the infected cells where conventional antibiotics struggle to reach.
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 💊
The results of this study underscore the potential of heLDL-based drug delivery systems in enhancing the intracellular efficacy of antibiotics like Ceftiofur. By significantly improving drug stability, cellular uptake, and therapeutic outcomes in challenging infections such as MRSA, CEF-heLDLs offer a promising strategy for next-generation antibacterial therapies. Future research may explore scalability, formulation optimization, and clinical translation of heLDL nanocarriers for human use. Moreover, this platform could be adapted for other antibiotics or therapeutic agents, broadening its applicability in combating a variety of intracellular pathogens.
🔗 Visit: https://infectious-diseases-conferences.pencis.com
📩 Nominate Now: https://jut.li/XWmUe
Hashtags
#IntracellularInfection #AntibioticResistance #DrugDeliverySystem #Nanomedicine #Ceftiofur #heLDLs #LDLCarrier #SAvsCEF #MRSA #CellTargeting #BiomedicalInnovation #Nanocarriers #ReceptorMediatedUptake #Biodistribution #InVivoEfficacy #IntracellularBacteria #AntibacterialTherapy #TherapeuticNanoparticles #LysosomalTargeting #PharmaceuticalScience
No comments:
Post a Comment